淋巴细胞亚群在胃癌免疫检查点抑制剂治疗中的研究进展

doi:10.3969/j.issn.1004-616x.2024.01.014

摘要/Abstract

摘要： 胃癌是严重危害人类健康的恶性肿瘤，随着多项临床试验的成功，免疫检查点抑制剂已经广泛应用于晚期胃癌的治疗。但是如何选择预测效果好、样本简便易得且检测价格低廉的生物标志物对患者进行分层是现阶段胃癌免疫治疗所面临的问题。研究发现肿瘤浸润淋巴细胞和外周血淋巴细胞亚群对免疫治疗均具有较好的疗效预测作用，是具有临床应用潜力的生物标志物。本文就淋巴细胞亚群在胃癌免疫检查点抑制剂治疗中的研究进展进行综述。

关键词: 淋巴细胞亚群, 胃癌, 免疫治疗, 免疫检查点抑制剂

中图分类号:

R730.5

王馨焱, 刘晓玲, 贾军梅. 淋巴细胞亚群在胃癌免疫检查点抑制剂治疗中的研究进展[J]. 癌变·畸变·突变, 2024, 36(1): 80-83.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma(CheckMate 649):a randomised, open-label, phase 3 trial[J]. Lancet,2021, 398(10294):27-40.
[3] KONO K, NAKAJIMA S, MIMURA K. Current status of immune checkpoint inhibitors for gastric cancer[J]. Gastric Cancer, 2020, 23(4):565-578.
[4] AHMADZADEH M, JOHNSON L A, HEEMSKERK B, et al. Tumor antigen-specific CD8+T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired[J]. Blood, 2009, 114(8):1537-1544.
[5] ZHANG Y Z, YANG Y, CHEN Y R, et al. PD-L1:biological mechanism, function, and immunotherapy in gastric cancer[J]. Front Immunol, 2022, 13:1060497.
[6] LIU X T, HOGG G D, DENARDO D G. Rethinking immune checkpoint blockade:‘Beyond the T cell’[J]. J Immunother Cancer, 2021, 9(1):e001460.
[7] ZHANG A Z, YUAN X, LIANG W H, et al. Immune infiltration in gastric cancer microenvironment and its clinical significance[J]. Front Cell Dev Biol, 2021, 9:762029.
[8] HAN J Q, ZHAO L L, WU J Y, et al. Role of CD4+T, CD8+T cells, and CD4+T/CD8+T cell ratio in gastric cancer and its clinical significance[J].Appl Bionics Biomech, 2022, 2022:1094607.
[9] LIU Y T, SUN Z J. Turning cold tumors into hot tumors by improving T-cell infiltration[J]. Theranostics, 2021, 11(11):5365-5386.
[10] FARHOOD B, NAJAFI M, MORTEZAEE K. CD8+cytotoxic T lymphocytes in cancer immunotherapy:a review[J]. J Cell Physiol, 2019, 234(6):8509-8521.
[11] BALANÇA C C, SALVIONI A, SCARLATA C M, et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+CD4 T cells[J]. JCI Insight, 2021, 6(2):e142513.
[12] LI X, ZHAI J, SHEN Y K, et al. Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+T cells[J]. Cancer Immunol Immunother, 2022, 71(12):3057-3070.
[13] WANG F H, ZHANG X T, LI Y F, et al. The Chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J]. Cancer Commun, 2021, 41(8):747-795.
[14] PEREIRA M A, DE CASTRIA T B, RAMOS M F K P, et al. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer:prognosis and association with PD-L1 expression[J]. J Surg Oncol, 2021, 124(7):1040-1050.
[15] SHEN Y, TENG Y S, LV Y P, et al. PD-1 does not mark tumor-infiltrating CD8+T cell dysfunction in human gastric cancer[J]. J Immunother Cancer, 2020, 8(2):e000422.
[16] LIN F Y, CHEN H, JIANG T, et al. The effect of low-dose chemotherapy on the tumor microenvironment and its antitumor activity combined with anti-PD-1 antibody[J]. Immunotherapy, 2022:35259922.
[17] CHEN Y, JIA K R, SUN Y, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment[J]. Nat Commun, 2022, 13(1):4851.
[18] CHALABI M, VERSCHOOR Y L, VAN DE HAAR J, et al. 1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction(G/GEJ)adenocarcinoma:the PANDA study[J]. Ann Oncol, 2022, 33:S1106.
[19] KHAN M, AROOJ S, WANG H. NK cell-based immune checkpoint inhibition[J]. Front Immunol, 2020, 11:167.
[20] HSU J, HODGINS J J, MARATHE M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade[J]. J Clin Invest,2018, 128(10):4654-4668.
[21] GUO S W, HUANG C, HAN F F, et al. Gastric cancer mesenchymal stem cells inhibit NK cell function through mTOR signalling to promote tumour growth[J]. Stem Cells Int, 2021, 2021:9989790.
[22] KYRYSYUK O, WUCHERPFENNIG K W. Designing cancer immunotherapies that engage T cells and NK cells[J]. Annu Rev Immunol, 2023, 41:17-38.
[23] YAMASHITA K, IWATSUKI M, YASUDA-YOSHIHARA N, et al.Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer[J]. Br J Cancer,2021, 124(3):595-603.
[24] DUHEN T, DUHEN R, LANZAVECCHIA A, et al. Functionally distinct subsets of human FOXP3+Treg cells that phenotypically mirror effector Th cells[J]. Blood, 2012, 119(19):4430-4440.
[25] SHI L S, FENG M, DU S C, et al. Adenosine generated by regulatory T cells induces CD8+T cell exhaustion in gastric cancer through A2aR pathway[J]. Biomed Res Int, 2019, 2019:4093214.
[26] TADA Y, TOGASHI Y, KOTANI D, et al. Targeting VEGFR2 with Ramucirumab strongly impacts effector/activated regulatory T cells and CD8+T cells in the tumor microenvironment[J]. J Immunother Cancer,2018, 6(1):106.
[27] KWON M, AN M, KLEMPNER S J, et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer[J]. Cancer Discov, 2021, 11(9):2168-2185.
[28] WANG Q Y, XIE B, LIU S, et al. What happens to the immune microenvironment after PD-1 inhibitor therapy?[J]. Front Immunol,2021, 12:773168.
[29] KAMADA T, TOGASHI Y, TAY C, et al. PD-1+regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J].Proc Natl Acad Sci USA, 2019, 116(20):9999-10008.
[30] GREENBERG P D, KERN D E, CHEEVER M A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2-T cells. Tumor eradication does not require participation of cytotoxic T cells[J]. J Exp Med, 1985, 161(5):1122-1134.
[31] ESCORS D, BOCANEGRA A, CHOCARRO L, et al. Systemic CD4immunity and PD-L1/PD-1 blockade immunotherapy[J]. Int J Mol Sci,2022, 23(21):13241.
[32] HELMINK B A, REDDY S M, GAO J J, et al. B cells and tertiary lymphoid structures promote immunotherapy response[J]. Nature, 2020,577(7791):549-555.
[33] GOU M M, QU T T, WANG Z K, et al. Neutrophil-to-lymphocyte ratio(NLR)predicts PD-1 inhibitor survival in patients with metastatic gastric cancer[J]. J Immunol Res, 2021, 2021:2549295.
[34] YUAN J J, ZHAO X W, LI Y Y, et al. The association between blood indexes and immune cell concentrations in the primary tumor microenvironment predicting survival of immunotherapy in gastric cancer[J]. Cancers, 2022, 14(15):3608.
[35] KIM K H, CHO J, KU B M, et al. The first-week proliferative response of peripheral blood PD-1+CD8+T cells predicts the response to antiPD-1 therapy in solid tumors[J]. Clin Cancer Res, 2019, 25(7):2144-2154.
[36] ABDOLAHI S, GHAZVINIAN Z, MUHAMMADNEJAD S, et al.Adaptive NK cell therapy modulated by anti-PD-1 antibody in gastric cancer model[J]. Front Pharmacol, 2021, 12:733075.
[37] NOSE Y, SAITO T, YAMAMOTO K, et al. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1therapy in gastric cancer[J]. Cancer Immunol Immunother, 2023, 72(1):169-181.
[38] SHEN R L, POSTOW M A, ADAMOW M, et al. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade[J]. Sci Transl Med, 2021, 13(608):eabf5107.
[39] OHMURA H, YAMAGUCHI K, HANAMURA F, et al. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody[J]. Br J Cancer, 2020, 122(10):1507-1517.
[40] LOZANO A X, CHAUDHURI A A, NENE A, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma[J]. Nat Med, 2022, 28(2):353-362.
[41] ZHU C Q, SHI Y Y, LI Q P, et al. Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect[J]. J Control Release, 2022, 341:769-781.
[42] WANG Y Y, ZHU C C, SONG W, et al. PD-L1 expression and CD8+T cell infiltration predict a favorable prognosis in advanced gastric cancer[J]. J Immunol Res, 2018, 2018:4180517.
[43] THOMPSON E D, ZAHURAK M, MURPHY A, et al. Patterns of PD-L1 expression and CD8+T cell infiltration in gastric adenocarcinomas and associated immune stroma[J]. Gut, 2017, 66(5):794-801.
[44] WANG J T, LI R C, CAO Y F, et al. Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer[J]. Nat Commun, 2021, 12(1):3080.